Are Options Traders Betting on a Big Move in Avadel Pharmaceuticals Stock?
Investors need to pay close attention to Avadel Pharmaceuticals stock based on the movements in the options market lately.
Avadel ( AVDL ) Q2 Revenue Jumps 64%
Avadel Pharmaceuticals Plc ( NASDAQ:AVDL ) , a biopharmaceutical company focused on transforming medicines to improve lives, released its earnings for Q2 2025 on August 7, 2025. The headline news is significant: the company delivered GAAP revenue and earnings that exceeded Wall Street's ...
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz - Avadel Pharmaceuticals ( NASDAQ:AVDL )
ASL estimates Avadel missed $600 million-$800 million in revenue by delaying Lumryz patient conversion. The company's market cap dropped from $2.5 billion to $900 million as CEO compensation reached $7.4 million. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this ...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
DUBLIN, June 30, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit ( the "Appeals ...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, June 30, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit ( the "Appeals Court" ) affirmed ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DUBLIN, June 16, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to two new ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, June 16, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to two new employees to purchase ...
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ ( sodium oxybate ) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
DUBLIN, June 05, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation ( ODD ) from the U.S.
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, Ireland, May 29, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on ...
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
DUBLIN, May 13, 2025 ( GLOBE NEWSWIRE ) -- DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer.
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, May 13, 2025 ( GLOBE NEWSWIRE ) -- DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer.
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DUBLIN, April 10, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine ( 9 ) new ...
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
DUBLIN, April 08, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, April 08, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
DUBLIN, April 01, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare ...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
DUBLIN, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m.
Aging Population Fuels Nocturia Market Growth, Projected to Reach US$ 8.5 Billion by 2034 - Latest Research Report by TMR
Wilmington, Delaware, Transparency Market Research Inc. -, Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- The global nocturia market ( Pasar Nocturia ) , valued at US$ 3.7 billion in 2023, is projected to grow at a CAGR of 8.0%, reaching US$ 8.5 billion by 2034.
Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement
DUBLIN, Ireland, Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and ...
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , iShares Biotechnology ETF ( NASDAQ:IBB )
Sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. AVDL expects net product revenue for 2025 in the range of $240 million to $260 million. Avadel Pharmaceuticals AVDL slipped by 25.63% in after-hours on Wednesday after it missed the fourth quarter sales estimate by 5.12%.
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch - Avadel Pharmaceuticals ( NASDAQ:AVDL )
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the ...
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the ...
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
DUBLIN, Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m.
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
DUBLIN, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference ...
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on ...
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
DUBLIN, Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S. District Court for the District of Columbia ( "Court" ) ruled in favor of the Food and ...
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Carvana ( NYSE:CVNA )
Shares of Carvana Co. CVNA rose in today's pre-market trading after the company reported better-than-expected third-quarter financial results. Carvana reported third-quarter revenue of $3.66 billion, beating the consensus estimate of $3.45 billion, according to Benzinga Pro.
Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) announced that the FDA has approved its supplemental new drug application ( sNDA ) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness EDS in patients ...
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ ( sodium oxybate ) Extended-Release Oral Suspension ( CIII ) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness ( EDS ) in patients 7 years of age and older with ...
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing ( sodium oxybate ) Extended-Release Oral Suspension ( CIII ) - Avadel Pharmaceuticals ( NASDAQ:AVDL )
- Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens - - 91% reported being better able to sleep through the night after switching to LUMRYZ -
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: ...
Stocks Showing Rising Market Leadership: Avadel Pharmaceuticals Earns 81 RS Rating
Avadel Pharmaceuticals ( AVDL ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday.
Looking At Avadel Pharmaceuticals's Recent Unusual Options Activity - Avadel Pharmaceuticals ( NASDAQ:AVDL )
Deep-pocketed investors have adopted a bearish approach towards Avadel Pharmaceuticals AVDL, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as ... - PR Newswire
QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as ... PR ...
Stocks To Watch: Avadel Pharmaceuticals Sees Relative Strength Rating Rise To 85
On Wednesday, Avadel Pharmaceuticals ( AVDL ) reached an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 85, up from 79 the day before.
Avadel Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Benchmark
Avadel Pharmaceuticals Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
DUBLIN, Ireland, May 01, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m.
3 No-Brainer Stocks to Buy With $300 Right Now
A modest amount of money can go a long way on Wall Street when it's put to work in time-tested businesses with well-defined catalysts.
Stocks With Rising Relative Price Strength: Avadel Pharmaceuticals
On Tuesday, Avadel Pharmaceuticals ( AVDL ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 88 to 91. X IBD's unique RS Rating measures market leadership by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price action over the last 52 weeks matches ...
Bitcoin To Hit $150K By Year-End, Says Fundstrat's Tom Lee: '...A Beeline Back Towards Its Long-Term Trend Line'; Apple's iPhone Sales Dip 24% in China, Falls to Fourth Place Behind Vivo and Huawei - Top Headlines Today While US Was Sleeping
Bitcoin's Rally Captures El Salvador President Nayib Bukele's Attention, Holds The Line With Memes Bitcoin Could Hit $200K This Year, Says Bitwise CIO: 'There's Too Much Demand And Not Enough Supply' Gold Bull Peter Schiff Raises Red Flag For BTC Rally: 'If I Was Long Bitcoin, I Would Be Worried ...
American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday - American Airlines Gr ( NASDAQ:AAL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. boosted the price target for Avadel Pharmaceuticals plc AVDL from $21 to $25.
Avadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results - Avadel Pharmaceuticals ( NASDAQ:AVDL )
Avadel Pharmaceuticals plc AVDL reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday. Avadel Pharmaceuticals posted a quarterly loss of 32 cents per share, compared to market expectations for a loss of 29 cents per share.
Avadel Pharmaceuticals Issues Statement On Patent Litigation - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, Ireland, March 04, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware ( "Court" ) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™.
Avadel Pharmaceuticals Issues Statement On Patent Litigation
DUBLIN, Ireland, March 04, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware ( "Court" ) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding ...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31st, greater than 2,200 patients enrolled in RYZUPTM and more than 1,200 patients initiated therapy ...
Myasthenia Gravis Treatment Market Will Experience Growth, Reaching US$4.1 Billion by the End of 2030, Predicts Persistence Market Research
New York, Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Myasthenia Gravis Treatment Market Poised for Steady Growth, driven by Innovation and Rising Awareness
Here's Why You Should Invest in Avadel ( AVDL ) Stock Now
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
Insiders Buying Dorian LPG And 2 Other Stocks - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , KalVista Pharma ( NASDAQ:KALV )
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
